Pembrolizumab and lenvatinib in the treatment of recurrent ovarian carcinoma: A single institution experience
Pembrolizumab-lenvatinib therapy demonstrated favorable clinical benefit in recurrent, platinum resistant MSS/pMMR ovarian cancer, a group of patients in need of more therapeutic options.
Authors
- David Warshal
- Helen Toma
- Lauren Krill
- Chelsea Katz (ORCID: https://orcid.org/0000-0003-2401-2121)
- Rebeca Kelly
- Hannah Hong (ORCID: https://orcid.org/0009-0005-3305-3306)
- Hannah Diasti
Institutions
- Thomas Jefferson University Hospital (US)
- Cooper University Hospital (US)
- Cooper Medical School of Rowan University (US)
- Sidney Kimmel Cancer Center (US)
- Cooper University Health Care (US)
Publication Details
- Journal
- Gynecologic Oncology Reports
- Published
- 2025-07-19
- DOI
- https://doi.org/10.1016/j.gore.2025.101811
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00